POP-OUT | CLOSE
Jump to a Molecule:
P-glycoprotein

Keywords: multidrug resistance, cancer chemotherapy, P-glycoprotein, membrane transport

Introduction

Our environment is filled with toxic substances that attack our molecular machinery. Our cells protect themselves from these dangers in many ways. In some cases, they use enzymes to convert them into harmless compounds. In other cases, they sequester them safely out of the way. For others, cells build specialized pumps that find toxins and eject them outside, for safe disposal.

Clean Sweep

P-glycoprotein, shown here from PDB entry 3g61, is the most common molecular pump protecting our cells from toxic molecules. It sits in the cell membrane and searches for foreign hydrophobic molecules. When it finds one, it grabs the molecule in a pocket deep within the protein, and then flips to a new conformation. The new conformation has an opening towards the outside of the cell, and the molecule is ejected. The whole process is powered by ATP to ensure that everything happens in a timely manner.

Powerful Pump

Of course, to be effective in its job, P-glycoprotein needs to be able to eject many different types of molecules. Scientists have found the P-glycoprotein pumps hundreds of different molecules, ranging is size from tens to hundreds of atoms. Most are hydrophobic and are normally found in the membrane. These include many toxic molecules, but also important drugs like cyclosporin and anticancer drugs. Thus, the action of P-glycoprotein can be both beneficial and harmful, protecting us from toxins but also reducing the effectiveness of the therapeutic drugs we take. The role of P-glycoprotein in cancer chemotherapy is described on the next page.

 

Blocking the Pump

Cancer cells in metastatic cancers are often particularly difficult to treat because they have become resistant to many different anticancer drugs. In some cases, these cells gain their multidrug resistance by building extra P-glycoprotein, which continually ejects the anticancer drugs out of the cancer cells. Researchers are working hard to find ways to block P-glycoprotein in cancer cells, to make them susceptible to treatment. One way is to use antibodies such as the ones shown here from PDB entry 1bln. They bind to small regions on P-glycoprotein (shown in green) and block the motions needed for pumping. Another approach is to find drugs that lodge in the active site of the protein, blocking its action from the inside.

 

 
  
click on the above Jmol tab for an interactive visualization

  

Exploring the Structure

P-glycoprotein is composed of one long chain that folds into two similar halves. In these pictures, the first half of the protein is colored blue and the second half is colored green. A short segment of protein linking the two halves is not seen in this crystal structure, and is shown here with a dotted line in magenta. Notice how similar the two halves are, and how extensive the overlapping area is between the two halves. Researchers have proposed that a gene duplication occurred during the evolution of the protein to connect these two similar halves into one long protein.

Two separate structures of P-glycoprotein are shown here, PDB entries 3g60 on the left and 3g61 on the right, which were solved with two different drug molecules, shown here in red. Notice how they bind in slightly different locations in the large active site of the protein. You can click on the image above for an interactive jmol version. To explore the interaction of the drug molecules with the protein, you can use the Ligand explorer for the 3g60 ligand and the 3g61 ligand. Notice that the interactions are almost entirely hydrophobic.

Topics for further exploration

  1. Bacteria build many different types of pumps for ejecting toxic molecules. Can you find examples in the PDB? Do they use a similar scissor-like mechanism?
  2. Can you find other examples of possible gene duplications in the PDB?

  

Additional Reading

  1. S. V. Ambudkar, S. Dey, C. A. Hrycyna, M. Ramachandra, I. Pastan and M. M. Gottesman (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annual Review of Pharmacology and Toxicology 39, 361-398.
  2. G. Szakacs, J. K. Paterson, J. A. Ludwig, C. Booth-Genthe and M. M. Gottesman (2006) Targeting multidrug resistance in cancer. Nature Reviews Drug Discovery 5, 219-234.
  3. M. Hennessy and J. P. Spiers (2007) A primer on the mechanics of P-glycoprotein the multidrug transporter. Pharmacological Research 55, 1-15.


Discussed Structures


Related PDB IDs


© 2014 David Goodsell & RCSB Protein Data Bank